Canadian pharmacies take steps to mitigate shortage of prescription painkillers
Earlier this month Health Canada said the drugs that are in short supply include those that contain acetaminophen with oxycodone, such as Percocet, as well as acetaminophen with codeine, for instance Tylenol 3.
These medications are prescribed to treat a wide range of ailments, from root canals to chronic back pain.
The federal agency's notice said the shortage is caused by increased demand and manufacturing disruptions at some of Canada's largest pharmaceutical companies.
The Canadian Pharmacists Association says a significant resupply is anticipated in early August.
Shelita Dattani, senior vice president of pharmacy affairs and strategic engagement at Neighbourhood Pharmacy Association of Canada, said some pharmacies are capping supplies to 30 days to ensure there is enough for all patients.
Dattani, who also works as a pharmacist in Ottawa, said it's important not to abruptly discontinue access to an opioid prescribed for pain because it could result in a patient going through withdrawal.
She says there are alternative medications, but going on a new opioid is not a simple switch.
This report by The Canadian Press was first published July 29, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Public advisory - Unlicensed Mitolux UV sunlamps for Vitamin D may pose health risks Français
, /CNW/ - Summary Product: Unlicensed ultraviolet (UV) sunlamps Issue: Health products – Unauthorized product; Product safety What to do: Do not use unlicensed Mitolux UV sunlamps. Consult a health care professional if you have used any of these sunlamps and have concerns about your health. Check whether medical devices have been licensed for sale by searching Health Canada's Medical Devices Active Licence Listing. Report any health product-related side effects or complaints to Health Canada. Affected products Issue Health Canada is warning consumers that unlicensed ultraviolet (UV) sunlamps sold by Mitolux may pose health risks due to excessive and unsafe ultraviolet B (UVB) radiation levels. The devices are marketed to be a reliable source of natural Vitamin D. Too much exposure to UVB radiation from using Mitolux UV sunlamps can cause: skin reactions and burns eye damage premature skin aging skin cancer with repeated exposure It is illegal to advertise for sale, import for sale, or sell medical devices in Canada without appropriate licensing under the Medical Devices Regulations. Health Canada is asking companies that sell Mitolux UV sunlamps to immediately stop selling them. Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed. What you should do
The Market Online
4 hours ago
- The Market Online
Tilray expands access to medical cannabis extracts in Italy
Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, an Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries Tilray stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021 Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy. This content has been prepared as part of a partnership with Tilray Brands Inc., and is intended for informational purposes only. Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni's network of pharmaceutical, scientific and medical professionals in Italy. Founded in 1892 and headquartered in Florence, Molteni maintains operations in more than 40 countries and benefits from in-house manufacturing, research and development, regulatory, supply chain and commercial capabilities, opening the door for future partnerships with Tilray down the line. The new partnership complements Tilray's existing operations in Italy, in addition to presences in Germany, Portugal, Poland and the United Kingdom, with European cannabis revenue growing by 112 per cent in fiscal 2025. Leadership insights 'This partnership reflects our commitment to advancing patient care through strategic collaboration,' Rajnish Ohri, Tilray Brands' Managing Director, International, said in Wednesday's news release. 'By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.' About Tilray Brands Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries. Tilray stock (TSX:TLRY) las traded at C$1.32. The cannabis stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021. Join the discussion: Find out what everybody's saying about this Canadian cannabis stock on the Tilray Brands Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
The Market Online
6 hours ago
- The Market Online
200% opportunity NOW: How Novo Nordisk, Dryden Gold, and Puma could boost your portfolio
The stock market in 2025 resembles a chessboard of extremes. While volatility is shaking up markets, extraordinary opportunities are emerging in unexpected corners. Established giants are stumbling, but it is precisely sharp price declines that harbor explosive comeback potential. At the same time, commodity newcomers are catching the attention of investors, driven by a sharp rise in the price of gold. And global consumer brands? Their fundamental strength may surprise despite short-term turbulence. Three very different players perfectly illustrate this momentum: Danish pharmaceutical giant Novo Nordisk, Canadian gold explorer Dryden Gold, and Puma, a German sportswear manufacturer. Their stories could transform your portfolio. This article is disseminated in partnership with Apaton Finance GmbH. It is intended to inform investors and should not be taken as a recommendation or financial advice. Novo Nordisk – Why the slump seems exaggerated Last week, Novo Nordisk reported a stable second quarter. Revenue of DKK 24.2 billion represents an increase of 16% compared to the previous year, and profits also rose by 25%. Despite this robust result, the share price continued to slide, driven by the reduced annual forecast, which now predicts revenue growth of 8-14% instead of 13-21%, and the change of CEO. Market share losses for key products, such as Wegovy, to competitor Eli Lilly and illegal generic drugs were additional burdens. But that is only half the story. People are forgetting how profitable Novo is. Operating profit shot up 86% in the first half of the year, and net profit almost doubled. Wegovy grew by 67% in Q2 alone, exceeding expectations. The long-term potential is crucial. Obesity affects around 40% of US adults, and less than 1% are treated with medication globally. Novo dominates this growth market with its established products and an advanced pipeline, including products such as CagriSema and Amycretin. Lilly's setback with the weak study results for Orforglipron plays into Novo Nordisk's hands. Novo is currently trading at a price-to-earnings ratio (P/E) of around 12 for 2026, well below its three-year average of around 34. In comparison, its competitor Eli Lilly is valued at a P/E ratio of over 22 for the same period. Even with moderate assumptions of 8-10% growth, the valuation appears overly conservative. Even a return to the historical average P/E ratio of 20 would mean significant upside potential based on conservative earnings forecasts. Although high capital expenditure on production capacity is weighing on cash flow in the short term, it will secure market penetration in the long term. The profitable market leader on its growth path is currently available for EUR 42.52. Dryden Gold – Three reasons to pay attention Canadian exploration company Dryden Gold (TSXV:DRY) has significantly expanded its current capital measure. Instead of the originally planned amount, up to CAD 7.8 million will now flow into the coffers through the sale of various types of shares. The high demand underscores the market's interest. Major shareholder Centerra Gold is also securing its 9.9% stake once again through a top-up right. The fresh capital will flow directly into additional drilling in northwestern Ontario and cover operating costs. For investors, the successful capital measure signals clear confidence in the project. Current drilling results from the flagship Gold Rock project confirm the potential. Several high-grade gold discoveries, including 15.3 g/t over 1.45 m and 5.36 g/t over 5 m, reveal a complex system of repeating structures. These are not isolated but extend for approximately 1 km between the Jubilee and Laurentian target areas. Visible gold was even drilled at a depth of 238 m. The combination of high grades and wide distribution is architecturally similar to productive systems such as Red Lake. Dryden strategically controls a consolidated land package of approximately 70,000 ha in an established mining region of Ontario. Proximity to the Trans-Canada Highway and existing infrastructure keep exploration costs unusually low. Partnerships with First Nations minimize operational risks. With the current funding, the fully financed exploration program can progress rapidly and deliver further results in the near term. For investors, this is not a hype-driven story, but a methodical exploration with clear leverage points such as new zones, depth extensions, and confirmed repeatability of high-grade structures. Analysts at Couloir Capital have issued a price target of CAD 0.65. The stock is currently trading at CAD 0.205, offering more than 100% upside potential. Puma has responded to its recent disappointing quarterly figures. The new key managers are addressing core problems: Former Adidas CIO Andreas Hubert is taking over as COO of the supply chain, bringing with him 12 years of expertise in Asia. This should be crucial for the 'nextlevel' cost-cutting program. Basketball Vice President Archie McEachern, a former Nike manager, is to reposition the lucrative US streetwear division. At the same time, CEO Arthur Höld is demonstrating his confidence in the turnaround by purchasing over EUR 100,000 worth of shares and another EUR 110,000 worth of derivatives on Puma. These targeted appointments directly address the sore points of margin pressure and innovation gaps. The direct-to-consumer (DTC) segment, which is already growing at double-digit rates, up 9.2% in the second quarter with online sales up 19.4%, is becoming a margin lever. Every percentage point increase in the DTC share from the current 31% boosts profitability without wholesale discounts. At the same time, the Company is pushing ahead with its premium strategy. Speedcat sneakers featuring K-pop star Rosé are already achieving high sales figures in Asia and Europe. If Puma manages to increase its DTC share to 40%, roughly the same level as Nike, and anchor its premium positioning in running/basketball, EBIT margins of 8–10% are entirely realistic. The stock is trading at a value of 5.3x EV/EBITDA, compared to around 14x for Adidas and approximately 24x for Nike. Even with moderate assumptions such as a slight recovery in sales in 2026 and a margin of 7%, a re-rating to 8–10x EV/EBITDA appears plausible. That alone implies significant upside potential. The free cash flow yield of a good 13% also offers flexibility. With declining inventory costs and reduced capital expenditures now at EUR 250 million, Puma could either reduce its debt or buy back shares. The share is currently available for EUR 17.255, which is below the price paid by the Management Board. Market volatility in 2025 is opening up selective opportunities for bold investors. Despite short-term setbacks and a valuation correction, Novo Nordisk offers massive long-term growth potential in the profitable obesity market at a favorable P/E ratio. Dryden Gold impresses with strong drilling results, a strategic project location, and fresh capital, which will enable accelerated exploration with significant upside potential relative to the current price. Puma is setting clear levers for a higher-margin recovery with new personnel and a focus on DTC growth and a premium strategy, with the stock appearing extremely undervalued. Diversified, all three offer interesting opportunities, albeit with varying degrees of risk. Conflict of interest Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a 'Transaction'). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company. In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships. For this reason, there is a concrete conflict of interest. The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such. The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user. The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
